tiprankstipranks
Trending News
More News >
Ocular Therapeutix (OCUL)
NASDAQ:OCUL
US Market

Ocular Therapeutix (OCUL) Stock Forecast & Price Target

Compare
1,420 Followers
See the Price Targets and Ratings of:

OCUL Analyst Ratings

Strong Buy
10Ratings
Strong Buy
10 Buy
0 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Ocular
Therapeutix
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

OCUL Stock 12 Month Forecast

Average Price Target

$17.56
▲(153.03%Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Ocular Therapeutix in the last 3 months. The average price target is $17.56 with a high forecast of $22.00 and a low forecast of $14.00. The average price target represents a 153.03% change from the last price of $6.94.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","23":"$23","8.75":"$8.75","13.5":"$13.5","18.25":"$18.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$22.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.56,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$17.56</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,8.75,13.5,18.25,23],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.53,9.566153846153846,10.602307692307692,11.638461538461538,12.674615384615384,13.71076923076923,14.746923076923077,15.783076923076923,16.81923076923077,17.855384615384615,18.89153846153846,19.927692307692308,20.963846153846156,{"y":22,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.53,9.224615384615383,9.919230769230769,10.613846153846152,11.308461538461538,12.003076923076922,12.697692307692307,13.392307692307691,14.086923076923075,14.78153846153846,15.476153846153846,16.17076923076923,16.865384615384613,{"y":17.56,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.53,8.95076923076923,9.371538461538462,9.792307692307691,10.213076923076922,10.633846153846154,11.054615384615385,11.475384615384616,11.896153846153846,12.316923076923077,12.737692307692308,13.158461538461538,13.579230769230769,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.02,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.7,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.66,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.07,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.82,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.06,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.39,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.77,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.54,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.7,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.14,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.54,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.53,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$22.00Average Price Target$17.56Lowest Price Target$14.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on OCUL
TipRanks AITipRanks
Not Ranked
TipRanks
$7
Hold
0.86%
Upside
Reiterated
05/22/25
Ocular Therapeutix's overall score is primarily impacted by its financial performance, characterized by ongoing operational losses despite strong revenue growth. Technical analysis and valuation further weigh down the score due to bearish trends and profitability concerns. The earnings call provides some optimism with FDA approvals and a strong cash position, but delays and trial adjustments pose risks.
Bank of America Securities Analyst forecast on OCUL
Tazeen AhmadBank of America Securities
Bank of America Securities
$17
Buy
144.96%
Upside
Reiterated
05/19/25
Ocular Therapeutix (OCUL) Gets a Buy from Bank of America Securities
Scotiabank Analyst forecast on OCUL
Greg HarrisonScotiabank
Scotiabank
$22
Buy
217.00%
Upside
Reiterated
05/06/25
Ocular Therapeutix (OCUL) Gets a Buy from Scotiabank
H.C. Wainwright Analyst forecast on OCUL
Yi ChenH.C. Wainwright
H.C. Wainwright
$15
Buy
116.14%
Upside
Reiterated
05/06/25
Ocular Therapeutix: Promising Pipeline and Strategic Developments Justify Buy Rating Despite Current Financial Challenges
Raymond James Analyst forecast on OCUL
Dane LeoneRaymond James
Raymond James
$19
Buy
173.78%
Upside
Reiterated
05/05/25
Raymond James reiterates Strong Buy Rating on Ocular Therapeutix (OCUL)Raymond James analyst Dane Leone reiterated a Strong Buy rating and $19.00 price target on Ocular Therapeutix (NASDAQ: OCUL).
William Blair
Buy
Reiterated
05/05/25
Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (NASDAQ: OCUL) and Dianthus Therapeutics (NASDAQ: DNTH)
Needham
$15$14
Buy
101.73%
Upside
Reiterated
05/05/25
Strategic Advancements and Financial Updates Drive Buy Rating for Ocular Therapeutix
TD Cowen
$14
Buy
101.73%
Upside
Reiterated
05/05/25
Optimistic Buy Rating for Ocular Therapeutix Driven by Streamlined Trials and Promising FDA Engagement
RBC Capital Analyst forecast on OCUL
Lisa WalterRBC Capital
RBC Capital
$17
Buy
144.96%
Upside
Reiterated
05/05/25
RBC Capital Sticks to Their Buy Rating for Ocular Therapeutix (OCUL)
Citizens JMP Analyst forecast on OCUL
Jonathan WollebenCitizens JMP
Citizens JMP
$19
Buy
173.78%
Upside
Reiterated
04/23/25
Citizens JMP reiterates Market Outperform Rating on Ocular Therapeutix (OCUL)Citizens JMP analyst Jonathan Wolleben reiterated a Market Outperform rating and $19.00 price target on Ocular Therapeutix (NASDAQ: OCUL).
Piper Sandler Analyst forecast on OCUL
Biren AminPiper Sandler
Piper Sandler
$21
Buy
202.59%
Upside
Reiterated
04/21/25
Piper Sandler Keeps Their Buy Rating on Ocular Therapeutix (OCUL)
Clear Street Analyst forecast on OCUL
William MaughanClear Street
Clear Street
$19
Buy
173.78%
Upside
Initiated
12/18/24
Clear Street starts Ocular Therapeutix (OCUL) at BuyClear Street analyst Bill Maughan initiates coverage on Ocular Therapeutix (NASDAQ: OCUL) with a Buy rating and a price target of $19.00.
Robert W. Baird Analyst forecast on OCUL
Colleen M. KusyRobert W. Baird
Robert W. Baird
$17
Buy
144.96%
Upside
Reiterated
12/03/24
Baird reiterates Outperform Rating on Ocular Therapeutix (OCUL)Baird analyst Colleen Kusy reiterated an Outperform rating and $17.00 price target on Ocular Therapeutix (NASDAQ: OCUL).
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on OCUL
TipRanks AITipRanks
Not Ranked
TipRanks
$7
Hold
0.86%
Upside
Reiterated
05/22/25
Ocular Therapeutix's overall score is primarily impacted by its financial performance, characterized by ongoing operational losses despite strong revenue growth. Technical analysis and valuation further weigh down the score due to bearish trends and profitability concerns. The earnings call provides some optimism with FDA approvals and a strong cash position, but delays and trial adjustments pose risks.
Bank of America Securities Analyst forecast on OCUL
Tazeen AhmadBank of America Securities
Bank of America Securities
$17
Buy
144.96%
Upside
Reiterated
05/19/25
Ocular Therapeutix (OCUL) Gets a Buy from Bank of America Securities
Scotiabank Analyst forecast on OCUL
Greg HarrisonScotiabank
Scotiabank
$22
Buy
217.00%
Upside
Reiterated
05/06/25
Ocular Therapeutix (OCUL) Gets a Buy from Scotiabank
H.C. Wainwright Analyst forecast on OCUL
Yi ChenH.C. Wainwright
H.C. Wainwright
$15
Buy
116.14%
Upside
Reiterated
05/06/25
Ocular Therapeutix: Promising Pipeline and Strategic Developments Justify Buy Rating Despite Current Financial Challenges
Raymond James Analyst forecast on OCUL
Dane LeoneRaymond James
Raymond James
$19
Buy
173.78%
Upside
Reiterated
05/05/25
Raymond James reiterates Strong Buy Rating on Ocular Therapeutix (OCUL)Raymond James analyst Dane Leone reiterated a Strong Buy rating and $19.00 price target on Ocular Therapeutix (NASDAQ: OCUL).
William Blair
Buy
Reiterated
05/05/25
Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (NASDAQ: OCUL) and Dianthus Therapeutics (NASDAQ: DNTH)
Needham
$15$14
Buy
101.73%
Upside
Reiterated
05/05/25
Strategic Advancements and Financial Updates Drive Buy Rating for Ocular Therapeutix
TD Cowen
$14
Buy
101.73%
Upside
Reiterated
05/05/25
Optimistic Buy Rating for Ocular Therapeutix Driven by Streamlined Trials and Promising FDA Engagement
RBC Capital Analyst forecast on OCUL
Lisa WalterRBC Capital
RBC Capital
$17
Buy
144.96%
Upside
Reiterated
05/05/25
RBC Capital Sticks to Their Buy Rating for Ocular Therapeutix (OCUL)
Citizens JMP Analyst forecast on OCUL
Jonathan WollebenCitizens JMP
Citizens JMP
$19
Buy
173.78%
Upside
Reiterated
04/23/25
Citizens JMP reiterates Market Outperform Rating on Ocular Therapeutix (OCUL)Citizens JMP analyst Jonathan Wolleben reiterated a Market Outperform rating and $19.00 price target on Ocular Therapeutix (NASDAQ: OCUL).
Piper Sandler Analyst forecast on OCUL
Biren AminPiper Sandler
Piper Sandler
$21
Buy
202.59%
Upside
Reiterated
04/21/25
Piper Sandler Keeps Their Buy Rating on Ocular Therapeutix (OCUL)
Clear Street Analyst forecast on OCUL
William MaughanClear Street
Clear Street
$19
Buy
173.78%
Upside
Initiated
12/18/24
Clear Street starts Ocular Therapeutix (OCUL) at BuyClear Street analyst Bill Maughan initiates coverage on Ocular Therapeutix (NASDAQ: OCUL) with a Buy rating and a price target of $19.00.
Robert W. Baird Analyst forecast on OCUL
Colleen M. KusyRobert W. Baird
Robert W. Baird
$17
Buy
144.96%
Upside
Reiterated
12/03/24
Baird reiterates Outperform Rating on Ocular Therapeutix (OCUL)Baird analyst Colleen Kusy reiterated an Outperform rating and $17.00 price target on Ocular Therapeutix (NASDAQ: OCUL).
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ocular Therapeutix

1 Month
xxx
Success Rate
17/41 ratings generated profit
41%
Average Return
+1.93%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 41.46% of your transactions generating a profit, with an average return of +1.93% per trade.
3 Months
xxx
Success Rate
8/16 ratings generated profit
50%
Average Return
+10.00%
reiterated a xxx
rating 6 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +10.00% per trade.
1 Year
Yi ChenH.C. Wainwright
Success Rate
11/22 ratings generated profit
50%
Average Return
+28.35%
reiterated a buy rating 23 days ago
Copying Yi Chen's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +28.35% per trade.
2 Years
xxx
Success Rate
10/16 ratings generated profit
63%
Average Return
+26.64%
reiterated a xxx
rating 6 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 62.50% of your transactions generating a profit, with an average return of +26.64% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

OCUL Analyst Recommendation Trends

Rating
Jan 25
Feb 25
Mar 25
Apr 25
May 25
Strong Buy
11
10
13
14
20
Buy
1
0
0
1
2
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
12
10
13
15
22
In the current month, OCUL has received 22 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. OCUL average Analyst price target in the past 3 months is 17.56.
Each month's total comprises the sum of three months' worth of ratings.

OCUL Financial Forecast

OCUL Earnings Forecast

Next quarter’s earnings estimate for OCUL is -$0.36 with a range of -$0.38 to -$0.31. The previous quarter’s EPS was -$0.38. OCUL beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.28% of the time in the same period. In the last calendar year OCUL has Outperformed its overall industry.
Next quarter’s earnings estimate for OCUL is -$0.36 with a range of -$0.38 to -$0.31. The previous quarter’s EPS was -$0.38. OCUL beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.28% of the time in the same period. In the last calendar year OCUL has Outperformed its overall industry.

OCUL Sales Forecast

Next quarter’s sales forecast for OCUL is $13.90M with a range of $12.00M to $18.50M. The previous quarter’s sales results were $10.70M. OCUL beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.63% of the time in the same period. In the last calendar year OCUL has Outperformed its overall industry.
Next quarter’s sales forecast for OCUL is $13.90M with a range of $12.00M to $18.50M. The previous quarter’s sales results were $10.70M. OCUL beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.63% of the time in the same period. In the last calendar year OCUL has Outperformed its overall industry.

OCUL Stock Forecast FAQ

What is OCUL’s average 12-month price target, according to analysts?
Based on analyst ratings, Ocular Therapeutix’s 12-month average price target is 17.56.
    What is OCUL’s upside potential, based on the analysts’ average price target?
    Ocular Therapeutix has 153.03% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is OCUL a Buy, Sell or Hold?
          Ocular Therapeutix has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Ocular Therapeutix’s price target?
            The average price target for Ocular Therapeutix is 17.56. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $22.00 ,the lowest forecast is $14.00. The average price target represents 153.03% Increase from the current price of $6.94.
              What do analysts say about Ocular Therapeutix?
              Ocular Therapeutix’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of OCUL?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis